Skip to main content
Smart Investors Daily
LI

NASDAQ · LIMNW

Liminatus Pharma, Inc. Warrants

Healthcare · Biotechnology

$0.04

Up+$0.01 (+12.81%)

Updated Sep 13, 2026, 8:15 PM

SID Score

2.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
3.19M
P/E ratio
-9.06
Dividend yield
0.00%
52-week range
$0.04 – $0.11
Volume
555
Avg. volume
49.98K

Price performance

LIMNW price history

1M range · 8 trading sessions · Daily adjusted prices

LIMNW closed at $0.04 after 8 trading sessions, down 7.12% for the selected period.

Last close
$0.04
Period change
-7.12%
Period low
$0.04
Period high
$0.07
Daily close
View OHLC price history
LIMNW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$0.0599$0.0599$0.0435$0.0437555
Aug 31, 2026$0.0669$0.0669$0.0552$0.05522.05K
Aug 28, 2026$0.0619$0.067$0.0434$0.04351.86K
Aug 27, 2026$0.0676$0.0676$0.0676$0.06762.02K
Aug 26, 2026$0.045$0.045$0.037$0.0377.81K
Aug 21, 2026$0.0452$0.0452$0.0451$0.04514.96K
Aug 19, 2026$0.067$0.067$0.0583$0.058315.26K
Aug 17, 2026$0.0597$0.0597$0.045$0.04716.75K

Latest LIMNW news

The latest Smart Investors Daily articles mentioning LIMNW.

LIMNW research

Overview

Company profile and research snapshot.

Company profile

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.